Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary cancer predisposition due to variation(s) in the RAD51D gene. Pathogenic germline variation in RAD51D confers an autosomal dominant predisposition to tumor formation at multiple primary sites, including ovarian cancer, triple negative breast cancer and ER negative breast cancer.
Biomarker and diagnostic research for RAD51D-related cancer predisposition has been reported in the published literature.
No clinical trials have been registered for RAD51D-related cancer predisposition.
204 publications have been identified in PubMed for RAD51D-related cancer predisposition. Kisho has analyzed 119 by research type. Research spans Review / Meta-Analysis (53%), Epidemiology / Natural History (24%), and Basic Science / Preclinical (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 63 | 53% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:41 AM UTC
Common questions about RAD51D-related cancer predisposition
Disease patterns and progression |
28 |
24% |
Laboratory research | 19 | 16% |
Other research | 3 | 3% |
Testing and diagnosis research | 3 | 3% |
Patient case studies | 1 | 1% |
Clinical study results | 1 | 1% |
New treatment approaches | 1 | 1% |
Ekdahl Hjelm T (2026). [PMID: 42139642](https://pubmed.ncbi.nlm.nih.gov/42139642/). *JCO Glob Oncol*. [Epidemiology / Natural History]
Fu Y (2026). [PMID: 41386230](https://pubmed.ncbi.nlm.nih.gov/41386230/). *Cell Genom*. [Basic Science / Preclinical]
Zhang S (2026). [PMID: 41491598](https://pubmed.ncbi.nlm.nih.gov/41491598/). *Mol Cancer*. [Review / Meta-Analysis]
Wang L (2026). [PMID: 41106391](https://pubmed.ncbi.nlm.nih.gov/41106391/). *Cell Genom*. [Diagnostic / Biomarker]
Gjyrezi A (2026). [PMID: 41428387](https://pubmed.ncbi.nlm.nih.gov/41428387/). *Physiol Rev*. [Review / Meta-Analysis]
Guerrero JJG (2026). [PMID: 40833357](https://pubmed.ncbi.nlm.nih.gov/40833357/). *Int J Cancer*. [Review / Meta-Analysis]
Katz SJ (2025). [PMID: 40016666](https://pubmed.ncbi.nlm.nih.gov/40016666/). *BMC Cancer*. [Clinical Trial Publication]
Lepage M (2025). [PMID: 40022545](https://pubmed.ncbi.nlm.nih.gov/40022545/). *Mol Genet Genomic Med*. [Epidemiology / Natural History]
Matsuda T (2025). [PMID: 39938491](https://pubmed.ncbi.nlm.nih.gov/39938491/). *Digestion*. [Review / Meta-Analysis]
Tlemsani C (2025). [PMID: 39848894](https://pubmed.ncbi.nlm.nih.gov/39848894/). *Bull Cancer*. [Review / Meta-Analysis]